Canaccord Genuity set a $25.00 price target on Selecta Biosciences, Inc. (NASDAQ:SELB) in a research report report published on Wednesday morning. The brokerage currently has a buy rating on the stock.

Several other research firms have also weighed in on SELB. Zacks Investment Research raised Selecta Biosciences from a sell rating to a hold rating in a research note on Wednesday, July 12th. ValuEngine raised Selecta Biosciences from a sell rating to a hold rating in a research report on Friday, June 30th. Needham & Company LLC reaffirmed a buy rating and set a $28.00 price target on shares of Selecta Biosciences in a research report on Tuesday, March 28th. Finally, UBS AG reaffirmed a buy rating and set a $26.00 price target on shares of Selecta Biosciences in a research report on Thursday, March 30th. Two investment analysts have rated the stock with a hold rating and four have given a buy rating to the company. The stock currently has a consensus rating of Buy and a consensus price target of $26.00.

Selecta Biosciences (NASDAQ SELB) opened at 16.98 on Wednesday. Selecta Biosciences has a 1-year low of $10.26 and a 1-year high of $28.00. The firm’s 50-day moving average price is $18.07 and its 200 day moving average price is $14.84.

Selecta Biosciences (NASDAQ:SELB) last released its earnings results on Thursday, May 11th. The company reported ($0.82) earnings per share for the quarter, beating the consensus estimate of ($1.22) by $0.40. Selecta Biosciences had a negative return on equity of 76.21% and a negative net margin of 715.40%. The firm had revenue of $0.14 million for the quarter. On average, equities analysts predict that Selecta Biosciences will post ($3.34) earnings per share for the current year.

ILLEGAL ACTIVITY WARNING: This news story was originally reported by Watch List News and is the sole property of of Watch List News. If you are accessing this news story on another site, it was stolen and reposted in violation of United States & international copyright & trademark law. The legal version of this news story can be viewed at https://www.watchlistnews.com/selecta-biosciences-inc-selb-given-a-25-00-price-target-at-canaccord-genuity/1462350.html.

In other news, COO Lloyd P. Johnston sold 5,959 shares of the firm’s stock in a transaction dated Monday, July 3rd. The stock was sold at an average price of $19.10, for a total transaction of $113,816.90. Following the sale, the chief operating officer now owns 7,565 shares of the company’s stock, valued at $144,491.50. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, Director Timothy A. Springer purchased 16,104 shares of the company’s stock in a transaction dated Thursday, May 18th. The shares were acquired at an average cost of $14.00 per share, for a total transaction of $225,456.00. Following the transaction, the director now owns 11,244 shares of the company’s stock, valued at $157,416. The disclosure for this purchase can be found here. In the last ninety days, insiders have bought 355,413 shares of company stock worth $6,232,567 and have sold 321,819 shares worth $4,765,494.

Several large investors have recently added to or reduced their stakes in the company. Bank of New York Mellon Corp acquired a new stake in Selecta Biosciences during the first quarter worth approximately $211,000. Hikari Power Ltd acquired a new stake in Selecta Biosciences during the first quarter worth approximately $349,000. Candriam Luxembourg S.C.A. acquired a new stake in Selecta Biosciences during the first quarter worth approximately $444,000. Goldman Sachs Group Inc. raised its stake in Selecta Biosciences by 83.1% in the first quarter. Goldman Sachs Group Inc. now owns 31,588 shares of the company’s stock worth $452,000 after buying an additional 14,332 shares in the last quarter. Finally, UBS Group AG raised its stake in Selecta Biosciences by 1,215.9% in the first quarter. UBS Group AG now owns 71,361 shares of the company’s stock worth $1,022,000 after buying an additional 65,938 shares in the last quarter. 45.60% of the stock is currently owned by institutional investors.

Selecta Biosciences Company Profile

Selecta Biosciences, Inc is a clinical-stage biopharmaceutical company. The Company using its synthetic vaccine particle (SVP) technology to discover and develop targeted therapies that are designed to modulate the immune system to treat rare and serious diseases. The Company is engaged in the research and development of nanoparticle immunomodulatory drugs for the treatment and prevention of human diseases.

Receive News & Ratings for Selecta Biosciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Selecta Biosciences Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.